Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology & RAS/MAPK Pathway Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAPK3/ERK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase (WT & Mutant) | MAPK3/ERK1 Recombinant Kinase (WT & mutant variants). Full-length and kinase domain. >95% purity, endotoxin <1 EU/µg. Sequence verified. TEY-phosphorylated by constitutively active MEK1. | View MAPK3 Products |
| Gene Delivery | MAPK3 Promise-ORF / Lentivirus. Full-length ORF with dual-phosphorylation motif for stable cell line construction; CMV promoter with antibiotic selection. | View MAPK3 Products |
| Benchmark Ab | Anti-Phospho-ERK1/2 (Thr202/Tyr204) recombinant rabbit monoclonal. Validated reference control for western blot, IHC, IF. | View MAPK3 Products |
| Validator | MAPK3 siRNA Set (3 unique sequences, includes scrambled control). For knockdown verification and assay specificity controls. | View MAPK3 Products |
| Resistance Mutants | MAPK3 Mutant Panel (Q58P gatekeeper, G36V activation loop). Sequence verified; theoretical MW and pI provided. | View MAPK3 Products |
| Isoform Selectivity | MAPK1/ERK2 Recombinant Protein. Human full-length, >95% purity; LC-MS/MS verified; for ERK1 vs ERK2 profiling. | View MAPK1 Products |
| Upstream Kinase | MAP2K1/MEK1 Constitutively Active (S218D/S222D). Recombinant kinase for cascade activation assays and feedback studies. | View MAP2K1 Products |
| Negative Regulator | DUSP6/MKP-3 Recombinant Phosphatase. ERK1-specific dual-specificity phosphatase for dephosphorylation controls. | View DUSP6 Products |
| Related Target B | BRAF (WT & V600E mutant). Upstream kinase driving MAPK3 hyperactivation in melanoma and colorectal cancer. | View BRAF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ERK1 vs ERK2 Isoform Selectivity | Human MAPK3 and MAPK1 ortholog proteins available with >95% purity; LC-MS/MS verified; theoretical MW distinction. |
| Active Kinase Conformation (Phosphorylation) | Recombinant kinase phosphorylated by constitutively active MEK1; TEY motif phosphorylated; >95% purity; endotoxin <1 EU/µg. |
| Drug Resistance Mutation Screening | Sequence-verified gatekeeper (Q58P) and activation loop (G36V) mutants; theoretical pI/mass data provided. |
| Pathway Cascade Reconstruction | Matched constitutively active MEK1 (S218D/S222D) and ERK1 pair for signal propagation assays. |
| Assay Specificity Control | Validated Benchmark antibodies (p-ERK1/2) and siRNA set for knockdown confirmation; reduces false positives. |
| Off-target Safety (MAPK family panel) | Extended MAPK family protein panel (p38, JNK) for selectivity counter-screening; mass spec verified. |
Live MAPK3 (ERK1) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAPK3 (ERK1) therapeutics is intensifying, with the oncology field shifting focus from pan-MEK inhibition to vertical ERK blockade to overcome feedback reactivation and acquired resistance to upstream KRAS, BRAF, and MEK inhibitors. While first-generation ATP-competitive inhibitors (e.g., ulixertinib/BVD-523) advance through Phase II, next-generation R&D is targeting acquired resistance mutations (Q58P gatekeeper, G36V activation loop) and developing isoform-selective or allosteric ERK1/2 inhibitors to reduce toxicity. PROTAC degraders are emerging to eliminate both kinase-dependent and scaffolding functions. Combination strategies pairing ERK inhibitors with KRAS-G12C, BRAF, or MEK inhibitors are becoming the dominant clinical paradigm for solid tumors, particularly RAS-mutant colorectal, pancreatic, and lung cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ATP-Competitive Small Molecule Inhibitor | BioMed Valley Discoveries (Ulixertinib), Verrica Pharma | Solid Tumors (BRAF/KRAS mutant) | Biochemical Kinase Assay (need active phosphorylated ERK1, >95% purity) |
| Allosteric / Substrate-Competitive Inhibitor | iOnctura (IOA-289), Academic consortia | Hematologic Malignancies, Solid Tumors | Conformational Binding Assay (need mutant panel Q58P/G36V) |
| PROTAC Degrader | Preclinical Biotech spin-offs, Emerging Academic Programs | MEK-resistant Cancers, Refractory NSCLC, Melanoma | Ternary Complex Formation (need active protein with native folding, specific antibodies) |
| Combination Therapies (including Dual MEK/ERK) | Amgen, Mirati (KRAS combos); Array BioPharma (Dual MEK/ERK) | Colorectal Cancer, Pancreatic Cancer, Melanoma | Synergy Evaluation (need pathway controls, matched MEK1/ERK1 pair, validated cell tools) |